Tag:
European Medicines Agency
Latest Headlines
Latest Headlines
Biovest makes a move on the EU market with BiovaxID
Biovest International's stock has risen by 15% on two pieces of news about its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, BiovaxID.
Ex-EU drug watchdog head's consulting gig scrutinized
The European Medicines Agency has received some fresh requests to investigate former head Thomas Lonngren, who is now an industry consultant, for potential conflicts of interest committed before he
EMA boosts war on bad drug reactions in €222.5M budget
The European Medicines Agency (EMA) plans to scale up its battle against harmful drug reactions in 2012 after citing figures that the problem costs thousands of lives and €79 billion a year. The
J&J's blockbuster hopefuls get EMA recommendation
Johnson & Johnson ($JNJ) saw its stable of new drugs strengthened at last week's meeting of European regulators. The European Medicines Agency's drug-approval panel backed its new prostate cancer
Roche, Novartis cancer meds win EMA nod
Roche and Novartis both got a boost from European authorities, who are recommending new uses for their targeted cancer drugs. Roche got the nod from European Medicines Agency to market Tarceva for
EMA wants Actos warning, weighs in on Chantix
Regulators on both sides of the Atlantic issued a slew of decrees about drug safety, weighing in on everything from flu vaccine to bone drugs to Pfizer's smoking cessation med Chantix. The biggest
EMA broadens safety review on Sanofi's Multaq
It's not shaping up to be a great week for Sanofi ( $SNY ). Yesterday, the company announced that its multiple sclerosis drug candidate Lemtrada didn't meet its secondary endpoint in a clinical trial,
EMA nod for key new drugs from GSK, Merck, BMS
Three drugs recently approved in the U.S. to great fanfare have now won recommendations for sale in Europe. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use gave
EMA board vote leaves agency leaderless
If aliens land at the European Medicines Agency, they'll have trouble with their usual take-us-to-your-leader request. At its latest meeting, the agency's management board failed to agree on a new
EMA loosens limits on Avastin in breast cancer
When European drug regulators meet, their new decrees set off a slew of headlines. This week was no different. But among the recommendations and approvals and warnings, one stood out. The European
